These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 16875893)
41. Approach to management of atrial fibrillation in the Indian scenario. Vora A J Assoc Physicians India; 2007 Apr; 55 Suppl():30-2. PubMed ID: 18368864 [No Abstract] [Full Text] [Related]
42. New directions in the management of atrial fibrillation. Grace A Lancet; 2002 Feb; 359(9304):410. PubMed ID: 11844520 [No Abstract] [Full Text] [Related]
43. Incidence of atrial fibrillation post-cavotricuspid isthmus ablation in patients with typical atrial flutter: left-atrial size as an independent predictor of atrial fibrillation recurrence. Ellis K; Wazni O; Marrouche N; Martin D; Gillinov M; McCarthy P; Saad EB; Bhargava M; Schweikert R; Saliba W; Bash D; Rossillo A; Erciyes D; Tchou P; Natale A J Cardiovasc Electrophysiol; 2007 Aug; 18(8):799-802. PubMed ID: 17593230 [TBL] [Abstract][Full Text] [Related]
44. Antiarrhythmic drugs in the era of atrial fibrillation ablation. Boriani G; Mei DA; Imberti JF Europace; 2024 Jun; 26(6):. PubMed ID: 38700094 [No Abstract] [Full Text] [Related]
45. Atrial fibrillation is the most common sustained arrhythmia. Ruskin JN; Keane D Semin Interv Cardiol; 1997 Dec; 2(4):181-3. PubMed ID: 9704351 [No Abstract] [Full Text] [Related]
47. Lessons from catheter ablation: how a proarrhythmic effect has become a therapeutic chance. The case of class IC/III drugs in atrial flutter. Catanzariti D; Vergara G Ital Heart J; 2005 Jul; 6(7):591-4. PubMed ID: 16274022 [No Abstract] [Full Text] [Related]
51. [Long term drug therapy for the prevention of recurrence in atrial fibrillation]. Newman D; Gillis A; Gilbert M; Dorian P Can J Cardiol; 1996 Feb; 12 Suppl A():21A-26A. PubMed ID: 8673948 [No Abstract] [Full Text] [Related]
52. Clinical assessment of antiarrhythmic agents for paroxysmal atrial fibrillation guided by modification of electrophysiologic arrhythmogenicity. Cosío FG J Cardiovasc Electrophysiol; 2005 Jun; 16(6):677; author reply 677. PubMed ID: 15946374 [No Abstract] [Full Text] [Related]
53. Who, when and how to rate control for atrial fibrillation. Rienstra M; Van Gelder IC Curr Opin Cardiol; 2008 Jan; 23(1):23-7. PubMed ID: 18281823 [TBL] [Abstract][Full Text] [Related]
54. Regular supraventricular tachycardias associated with idiopathic atrial fibrillation. Gonzalez-Zuelgaray J; Perez A Am J Cardiol; 2006 Nov; 98(9):1242-4. PubMed ID: 17056338 [TBL] [Abstract][Full Text] [Related]
56. Dronedarone: in quest of the ideal antiarrhythmic drug. Kayser SR Prog Cardiovasc Nurs; 2007; 22(4):221-4. PubMed ID: 18059201 [No Abstract] [Full Text] [Related]
57. How safe is the antiarrhythmic drug therapy in atrial fibrillation? Krishnamoorthy S; Lip GY Europace; 2009 Jul; 11(7):837-9. PubMed ID: 19546182 [No Abstract] [Full Text] [Related]
58. [Antiarrhythmic drug therapy for atrial fibrillation]. Zhang JR; Li CY; Ma CS Zhonghua Nei Ke Za Zhi; 2021 Apr; 60(4):289-293. PubMed ID: 33765695 [TBL] [Abstract][Full Text] [Related]
59. Ablation of atrial fibrillation in congestive heart failure. Tung R; Boyle NG Minerva Cardioangiol; 2008 Dec; 56(6):653-7. PubMed ID: 19092740 [TBL] [Abstract][Full Text] [Related]
60. Cardiac resynchronization therapy in the setting of permanent atrial fibrillation and heart failure. Koneru JN; Steinberg JS Curr Opin Cardiol; 2008 Jan; 23(1):9-15. PubMed ID: 18281821 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]